Abstract
Peroxisomes contain a set of substrate-specific metabolic pathways, including the oxidation of a range of fatty acids, the biosynthesis of a special group of phospholipids (plasmalogens) and the production of bile acids. Clinically, a dysfunction of peroxisomes results in most cases in neurologic symptoms of varying extent, from severe to milder clinical forms. Ocular and hearing symptoms, dysmorphisms, liver disease and skeletal involvement are variably associated with these different disorders. Peroxisomal disorders are divided into two major categories. The first are disorders resulting from a failure to form normal peroxisomes, giving rise to multiple metabolic abnormalities. This group is named peroxisome biogenesis disorders (PBD) that can be divided into two subtypes, including (1) the Zellweger spectrum disorders and (2) rhizomelic chondrodysplasia punctata (RCDP) type 1. The second category includes the disorders, which result from the deficiency of a peroxisomal enzyme or transporter.
In single peroxisomal enzyme disorders, the basic problem is at the level of one of the enzymes or transporters involved in each of the different metabolic pathways contained in peroxisomes. Clinically, these disorders can be as severe as those in which peroxisomal biogenesis is defective. This is the case for D-bifunctional protein deficiency, peroxisomal acyl-CoA oxidase 1 deficiency and the RCDP types 2 and 3. The most common single peroxisomal enzyme disorder is the X-linked adrenoleukodystrophy (ALD)/adrenomyeloneuropathy (AMN) complex that consists of a spectrum of phenotypes varying in the age of onset and severity of clinical presentation.
The diagnosis of a peroxisomal disorder can be determined by a battery of biochemical assays in blood and/or urine and should be confirmed in cultured fibroblasts. Prenatal diagnosis is possible either by biochemical testing or by molecular analysis. Management of most peroxisomal disorders is focused on supportive care and multidisciplinary treatment of a variety of systemic complications. Specific treatment is essential in a few single enzyme disorders. Bone marrow/haematopoietic stem cell transplantation is an option for boys suffering from the cerebral form of X-ALD , at least when in the early stages.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aubourg P, Adamsbaum C, Lavallard-Rousseau MC et al (1993) A two-year trial of oleic and erucia acids (“Lorenzo’s oil”) as treatment for adrenomyeloneuropathy. N Engl J Med 329:745–752
Bams-Mengerink AM, Majoie CBLM, Duran M et al (2006) MRI of the brain and cervical spinal cord in rhizomelic chondrodysplasia punctata. Neurology 66:798–803
Barth PG, Wanders RJ, Schutgens RB et al (1996) Variant rhizomelic chondrodysplasia punctata (RCDP) with normal plasma phytanic acid: clinico-biochemical delineation of a subtype and complementation studies. Am J Med Genet 62:164–168
Barth PG, Gootjes J, Bode H et al (2001) Late onset white matter disease in peroxisome biogenesis disorder. Neurology 57:1949–1955
Bjorkhem I, Sisfontes L, Bostrom B et al (1986) Simple diagnosis of the Zellweger syndrome by gas–liquid chromatography of dimethylacetals. J Lipid Res 27:786–791
Braverman N, Chen L, Lin P et al (2002) Mutation analysis of PEX7 in 60 probands with rhizomelic chondrodysplasia punctata and functional correlations of genotype with phenotype. Hum Mutat 20:284–297
Carlton VE, Harris BZ, Puffenberger EG (2003) Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT. Nat Genet 34:91–96
Cartier N, Hacein-Bey-Abina S, Bartholomae C et al (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326:818–823
De Vet EC, Ijlst L, Oostheim W et al (1998) Alkyl-dihydroxyacetonephosphate synthase. Fate in peroxisome biogenesis disorders and identification of the point mutation underlying a single enzyme deficiency. J Biol Chem 273:10296–10301
Dick D, Horvath R, Chinnery PF et al (2011) AMACR mutations cause late-onset autosomal recessive cerebellar ataxia. Neurology 76:1768–1770
Ebberink MS, Mooijer PAW, Gootjes J et al (2010) Genetic classification and mutational spectrum of more than 600 patients with a Zellweger syndrome spectrum disorder. Hum Mutat 32:59–69
Ferdinandusse S, Denis S, Clayton PT et al (2000) Mutations in the gene encoding peroxisomal alpha-methylacyl-CoA racemase cause adult-onset sensory motor neuropathy. Nat Genet 24:188–191
Ferdinandusse S, Denis S, Mooyer PAW et al (2006a) Clinical and biochemical spectrum of D-bifunctional protein deficiency. Ann Neurol 59:92–104
Ferdinandusse S, Kostopoules P, Denis S et al (2006b) Mutations in the gene encoding peroxisomal sterol carrier protein X (SCPx) cause leukoencephalopathy with dystonia and motor neuropathy. Am J Hum Genet 78:1046–1052
Ferdinandusse S, Denis S, Hogenhout EM et al (2007) Clinical, biochemical, and mutational spectrum of peroxisomal acyl-coenzyme A oxidase deficiency. Hum Mutat 28:904–912
Gilbert EF, Opitz JM, Spranger JW et al (1976) Chondrodysplasia punctata-rhizomelic form. Pathologic and radiologic studies of three infants. Eur J Pediatr 123:89–109
Gould SJ, Valle D (2000) Peroxisome biogenesis disorders: genetics and cell biology. Trends Genet 16:340–345
Gould SJ, Raymond GV, Valk D (2001) The peroxisome biogenesis disorders. In: Scriver CR, Beaudet al, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3181–3217
Grønberg S, Krätzner R, Spiegler J et al (2010) Typical cMRI pattern as diagnostic clue for D-bifunctional protein deficiency without apparent biochemical abnormalities in plasma. Am J Med Genet A 152A:2845–2849
Jenkinson EM, Clayton-Smith J, Mehta S et al (2011) Perrault syndrome: further evidence for genetic heterogeneity. J Neurol. doi:10.1007/s00415-011-6285-5
Kapina V, Sedel F, Truffert A (2010) Relapsing rhabdomyolysis due to peroxisomal α-methylacyl-CoA racemase deficiency. Neurology 75:1300–1301
Kelley RI, Datta NS, Dobyns WB et al (1986) Neonatal adrenoleukodystrophy: new cases, biochemical studies, and differentiation from Zellweger and related peroxisomal polydystrophy syndromes. Am J Med Genet 23:869–901
Miller WP, Rothman SM, Nascene D et al (2011) Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institutional cohort report. Blood 1971–1978
Moser HW, Smith KD, Watkins PA (2001) X-linked adrenoleukodystrophy. In: Scriver CR, Beaudet al, Sly WS, Valle D (eds) The metabolic basis of inherited disease, 8th edn. McGraw-Hill, New York, pp 3257–3302
Moser HW, Raymond GV, Lu SE et al (2005) Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo’s oil. Arch Neurol 62:1073–1080
Motley AM, Brites P, Gerez L et al (2002) Mutational spectrum in the PEX7 gene and functional analysis of mutant alleles in 78 patients with rhizomelic chondrodysplasia punctata type 1. Am J Hum Genet 70:612–614
Ofman R, Hettema EH, Hogenhout EM et al (1998) Acyl-CoA: dihydroxyacetonephosphate acyltransferase: clowing of the human cDNA and resolution of the molecular basis in rhizomelic chondrodysplasia punctata type 2. Hum Mol Genet 7:847–853
Paker AM, Sunness JS, Brereton NH et al (2010) Docosahexaenoic acid therapy in peroxisomal diseases: results of a double-blind, randomized trial. Neurology 75:826–830
Pellicoro A, van den Heuvel FA, Geuken M et al (2007) Human and rat bile acid-CoA: amino acid N-acetyltransferase are liver-specific peroxisomal enzymes: implications for intracellular bile salt transport. Hepatology 45:340–348
Pierce SB, Walsh KM, Chisholm MK et al (2010) Mutations in the DBP-deficiency protein. HSD17B4 cause ovarian dysgenesis, hearing loss, and ataxia of Perrault syndrome. Am J Hum Genet 87:282–288
Poll-The BT, Gärtner J (2012) Clinical diagnosis, biochemical findings and MRI spectrum of peroxisomal disorders. Biochim Biophys Acta. doi:10.1007/s001090000086
Poll-The BT, Roels F, Ogier H et al (1988) A new peroxisomal disorder with enlarged peroxisomes and a specific deficiency of acyl-CoA oxidase (pseudo-neonatal adrenoleukodystrophy). Am J Hum Genet 42:422–434
Régal L, Ebberink MS, Goemans N et al (2010) Mutations in PEX10 are a cause of autosomal recessive ataxia. Ann Neurol 68:259–263
Roosewich H, Waterham HR, Wanders RJ et al (2006) Pitfall in metabolic screening in a patient with fatal peroxisomal beta-oxidation defect. Neuropediatrics 37:95–96
Setchell KD, Bragetti P, Zimmer-Nechemias L et al (1992) Oral bile acid treatment and the patient with Zellweger syndrome. Hepatology 15:198–207
Setchell KD, Heubi JE, Bove KE et al (2003) Liver disease caused by failure to racemize trihydroxycholestanoic acid: gene mutation and effect of bile acid therapy. Gastroenterology 124:217–232
Sevin C, Ferdinandusse S, Waterham HR et al (2011) Autosomal recessive cerebellar ataxia caused by mutations in the PEX2 gene. Orphanet J Rare Dis 6:8
Smeitink JA, Beemer FA, Espiel M et al (1992) Bone dysplasia associated with phytanic acid accumulation and deficient plasmalogen synthesis: a peroxisomal entity amenable to plasmapheresis. J Inherit Metab Dis 15:377–380
Smith KD, Kemp S, Braiterman LT et al (1999) X-linked adrenoleukodystrophy: genes, mutations, and phenotypes. Neurochem Res 24:521–535
Soorani-Lunsing RJ, van Spronsen FJ, Stolte-Dijkstra I et al (2005) Normal very-long-chain fatty acids in peroxisomal D-bifunctional protein deficiency: a diagnostic pitfall. J Inherit Metab Dis 28:1172–1174
Suzuki Y, Jiang LL, Souri M et al (1997) D-3-hydroxyacyl-CoA dehydratase/D-3-hydroxyacyl-CoA dehydrogenase bifunctional protein deficiency a newly identified peroxisomal disorder. Am J Hum Genet 61:1153–1162
Tabak HF, Murk JL, Braakman I et al (2003) Peroxisomes start their life in the endoplasmic reticulum. Traffic 4:512–518
Thompson SA, Calvin J, Hagg S et al (2008) Relapsing encephalopathy in a patient with α-methylacyl-CoA racemase deficiency. J Neurol Neurosurg Psychiatry 79:448–450
van Grunsven EG, van Berkel E, Ijlst L et al (1998) Peroxisomal D-hydroxyacyl-CoA dehydrogenase deficiency: resolution of the enzyme defect and its molecular basis in bifunctional protein deficiency. Proc Natl Acad Sci U S A 95:2128–2133
Vreken P, Valianpour F, Overmars H et al (2000) Analysis of plasmanylethanolamines using electrospray tandem mass spectrometry and its application in screening for peroxisomal disorders. J Inherit Metab Dis 23:429–433
Wanders RJ, Waterham HR (2006) Biochemistry of mammalian peroxisomes revisited. Annu Rev Biochem 75:295–332
Wanders RJA, van Grunsven EG, Jansen GA (2000) Lipid metabolism in peroxisomes: enzymology, functions and dysfunctions of the fatty acid alpha- and beta-oxidation systems in humans. Biochem Soc Trans 28:141–149
Wanders RJA, Barth PG, Heymans HAS (2001a) Single peroxisomal enzyme deficiencies. In: Scriver CR, Beaudet al, Sly WS, Valle D (eds) The metabolic & molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3219–3256
Wanders RJA, Jakobs C, Skjeldal OH (2001b) Refsum disease. In: Scriver CR, Beaudet al, Sly WS, Valle D (eds) The metabolic & molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3303–3321
Waterham HR, Koster J, van Roermund CWT (2007) A lethal defect of mitochondrial and peroxisomal fission. N Engl J Med 356:1736–1741
Wierzbicki AS, Lloyd MD, Schofield CJ et al (2002) Refsum’s disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation. J Neurochem 80:727–735
Acknowledgements
The authors gratefully acknowledge Mrs. Maddy Festen-Sidler and Mrs. J.A. van Leeuwen-Wesselingh for their expert preparation of the manuscript and Mr. J.P.N. Ruiter for the artwork. Supported by grants from the Dutch Organisation for Scientific Research (NWO), Medical Sciences, the European Leukodystrophy Association (Project no FP7-Health-2009-single-stage-241622), the European Union Peroxisome Project (Project no LSHG-CT-2004-512018) and the Prinses Beatrix Fonds (Project no MAR-03-216), Den Haag, the Netherlands.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Poll-The, B.T., Wanders, R.J.A. (2014). Peroxisomal Disorders. In: Blau, N., Duran, M., Gibson, K., Dionisi Vici, C. (eds) Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-40337-8_24
Download citation
DOI: https://doi.org/10.1007/978-3-642-40337-8_24
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-40336-1
Online ISBN: 978-3-642-40337-8
eBook Packages: MedicineMedicine (R0)